| Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes I Caruana, B Savoldo, V Hoyos, G Weber, H Liu, ES Kim, MM Ittmann, ... Nature medicine 21 (5), 524-529, 2015 | 724 | 2015 |
| Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety V Hoyos, B Savoldo, C Quintarelli, A Mahendravada, M Zhang, J Vera, ... Leukemia 24 (6), 1160-1170, 2010 | 632 | 2010 |
| Armed oncolytic virus enhances immune functions of chimeric antigen receptor–modified T cells in solid tumors N Nishio, I Diaconu, H Liu, V Cerullo, I Caruana, V Hoyos, ... Cancer research 74 (18), 5195-5205, 2014 | 329 | 2014 |
| Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells E Yvon, M Del Vecchio, B Savoldo, V Hoyos, A Dutour, A Anichini, G Dotti, ... Clinical Cancer Research 15 (18), 5852-5860, 2009 | 177 | 2009 |
| Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia C Quintarelli, G Dotti, B De Angelis, V Hoyos, M Mims, L Luciano, ... Blood, The Journal of the American Society of Hematology 112 (5), 1876-1885, 2008 | 151 | 2008 |
| High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells C Quintarelli, G Dotti, ST Hasan, B De Angelis, V Hoyos, S Errichiello, ... Blood, The Journal of the American Society of Hematology 117 (12), 3353-3362, 2011 | 116 | 2011 |
| Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects P Shafer, LM Kelly, V Hoyos Frontiers in immunology 13, 835762, 2022 | 113 | 2022 |
| Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7 JF Vera, V Hoyos, B Savoldo, C Quintarelli, GMPG Attianese, AM Leen, ... Molecular Therapy 17 (5), 880-888, 2009 | 106 | 2009 |
| CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation P Bajgain, S Tawinwung, L D’Elia, S Sukumaran, N Watanabe, V Hoyos, ... Journal for immunotherapy of cancer 6, 1-13, 2018 | 104 | 2018 |
| In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor GMP Giordano Attianese, V Marin, V Hoyos, B Savoldo, I Pizzitola, ... Blood, The Journal of the American Society of Hematology 117 (18), 4736-4745, 2011 | 104 | 2011 |
| An inducible caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells S Yagyu, V Hoyos, F Del Bufalo, MK Brenner Molecular Therapy 23 (9), 1475-1485, 2015 | 102 | 2015 |
| T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo C Geldres, B Savoldo, V Hoyos, I Caruana, M Zhang, E Yvon, ... Clinical Cancer Research 20 (4), 962-971, 2014 | 99 | 2014 |
| The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies V Hoyos, I Borrello Blood, The Journal of the American Society of Hematology 128 (13), 1679-1687, 2016 | 73 | 2016 |
| 3D modeling of human cancer: A PEG-fibrin hydrogel system to study the role of tumor microenvironment and recapitulate the in vivo effect of oncolytic adenovirus F Del Bufalo, T Manzo, V Hoyos, S Yagyu, I Caruana, J Jacot, ... Biomaterials 84, 76-85, 2016 | 73 | 2016 |
| Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity M Ando, V Hoyos, S Yagyu, W Tao, CA Ramos, G Dotti, MK Brenner, ... Cancer gene therapy 21 (11), 472-482, 2014 | 56 | 2014 |
| Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer SA Nalawade, P Shafer, P Bajgain, MK McKenna, A Ali, L Kelly, J Joubert, ... Journal for immunotherapy of cancer 9 (11), 2021 | 49 | 2021 |
| Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity MK McKenna, A Englisch, B Brenner, T Smith, V Hoyos, M Suzuki, ... Molecular Therapy 29 (5), 1808-1820, 2021 | 44 | 2021 |
| Mesenchymal stromal cells for linked delivery of oncolytic and apoptotic adenoviruses to non-small-cell lung cancers V Hoyos, F Del Bufalo, S Yagyu, M Ando, G Dotti, M Suzuki, ... Molecular Therapy 23 (9), 1497-1506, 2015 | 42 | 2015 |
| Genetic modification of human T lymphocytes for the treatment of hematologic malignancies V Hoyos, B Savoldo, G Dotti Haematologica 97 (11), 1622, 2012 | 33 | 2012 |
| Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas CM Arnone, VA Polito, A Mastronuzzi, A Carai, FC Diomedi, L Antonucci, ... Journal for ImmunoTherapy of Cancer 9 (5), 2021 | 28 | 2021 |
